Sp111
DEVELOPING A CAREER IN QUALITY
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
This session is designed to demonstrate successful quality improvement in practices and across institutions with the focus on and meaningful real world implementation across a range of GI conditions. This session will discuss how to translate clinical research into quality improvement initiatives leading to successful improvement in patient outcomes. Attendees will also be able to incorporate feedback to improve patient satisfaction as well as reimbursement strategies as well as improving healthcare for socially disadvantaged populations and women's health.
This session is designed to demonstrate successful quality improvement in practices and across institutions with the focus on and meaningful real world implementation across a range of GI conditions. This session will discuss how to translate clinical research into quality improvement initiatives leading to successful improvement in patient outcomes. Attendees will also be able to incorporate feedback to improve patient satisfaction as well as reimbursement strategies as well as improving healthcare for socially disadvantaged populations and women's health.
Presenter
Tracks
Related Products
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Q&A
This session is designed to demonstrate successful quality improvement in practices and across institutions with the focus on and meaningful real world implementation across a range of GI conditions…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
